Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial

Regulatory filings expected in first half of 2020

- PMLiVE

How can we realise the benefits of patient engagement?

By Stephen O’Farrell and Nadine van Dongen

- PMLiVE

Vertex scores CF deal with Scotland, but access debate continues

Pressure to reach a deal in England mounts

- PMLiVE

Roche preps filings for Herceptin/Perjeta combination

Potential defence against biosimilar competition

- PMLiVE

IQVIA and partners set up cancer ‘data hub’ to speed up research

Seven research centres to be rolled out across UK

Roche Basel Switzerland

Roche presents new data in NMOSD, could challenge Alexion’s Soliris

Reduced risk of relapse by 55%

- PMLiVE

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

Sets up regulatory filings and possible approval next year

Biomarin

NICE approves BioMarin’s Brineura after initial setback

First treatment for rare disease

- PMLiVE

Gracell reports impressive data with one-day CAR-T for leukaemia

Takes fight to Novartis and Gilead

Article: Like, Like, Like: Harnessing the power of social media insights

Given the colossal amount of personal and professional information that we share online, social media channels such as Facebook and Twitter are fast becoming treasure troves of big data. As...

Inizio

- PMLiVE

Lucid Group acquires HealthCare21

Expands reach in UK, Asia Pacific and Middle East

- PMLiVE

Lucid Group increases footprint in UK, Asia Pacific and Middle East with the acquisition of HealthCare21

Lucid Group is delighted to announce its latest acquisition, welcoming colleagues from Healthcare consultancy HealthCare21 into its magic kingdom.Over the last twelve years, Lucid Group has become well known and...

Lucid Group Communications Limited

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links